Beremagene geperpavec
PreclinicalGene therapy
Beremagene geperpavec is a gene therapy that works as a COL7A1 Gene Therapy.[2] It is being investigated across 1 indication, with its most advanced program in Preclinical.[1]
Beremagene geperpavec is one of 12 gene therapy programs targeting Epidermolysis Bullosa. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Epidermolysis Bullosa
#DrugCompanyPhaseTrials
1Fludara
SanofiApproved
Busulfex
Akero TherapeuticsApproved
Cytoxan
BBaxter Healthcare Corporation
Approved
Accutane
CConrado Roberto Hoffmann Filho
Approved
E-Mycin
AAzurity Pharmaceuticals
Approved
Allo-APZ2-OTS
RRHEACELL GmbH & Co. KG
Phase 3
Oleogel-S10
Chiesi Farmaceutici S.p.A.Phase 3
Fludara
SanofiPreclinical
Garamycin
SSchering-Plough
Phase 2
Naropin
FFresenius Kabi USA, LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Beremagene geperpavec. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- COL7A1 Gene Therapy[2]
- Modality
- Gene therapy[2]
- Highest Phase
- Preclinical[1]
- Company
- KKrystal Biotech, Inc.